Navigation Links
Novexel to be Acquired by AstraZeneca
Date:12/23/2009

rica. - NXL103, an oral Streptogramin antibiotic. NXL103 is currently in a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid. NXL103 has already delivered positive Phase II results in a trial evaluating it in the treatment of community acquired pneumonia (CAP).

In addition, Novexel has two further programmes in preclinical development: NXL105, a novel anti-Pseudomonal antibiotic and NXL201, a novel echinocandin antifungal agent.

Iain Buchanan, Novexel's CEO, said, "Today's announcement highlights the significant progress that Novexel has made since it was spun out of Aventis Pharma S.A. in December 2004 and demonstrates the added value of placing promising assets in an entrepreneurial structure in France. Over the last five years we have made the appropriate decisions to advance the pipeline and I would like to pay tribute to all Novexel employees whose collective efforts have made this transaction with AstraZeneca possible. I am confident that the acquired assets will receive continued investment from both AstraZeneca and Forest and will have the possibility to play an important therapeutic role to combat resistant organisms in the hospital."

Goldman Sachs acted as financial advisor to Novexel on this transaction.

Notes to Editors

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for

novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimate
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
3. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
6. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/rt3mhz/deciphering ... "Deciphering Global Major Pharmaceutical Companies, New Outsourcing Demands ... It has been publicly recognized that global ... series of challenges in the recent years. The ... in small molecule product manufacturing; increasingly challenging process ...
(Date:7/7/2015)... 7, 2015   Decision Resources Group ... dialysis patient management in the U.S. versus the ... U.S. and EU5 nephrologists from approximately 1,870 dialysis ... the most commonly used renal medications in dialysis ... considerably between the two regions.      Other ...
(Date:7/7/2015)... BANGALORE , July 7, 2015 ... innovative clinical trial data management solutions, has been featured ... publication named " EDC and eCOA / ePRO Market ... is one of the leading providers of research and ... 22 EDC and eCOA / ePRO tools in the ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... Minimally Invasive Surgery Symposium (MISS) will include discussion of ... surgery, single-port bariatric surgery, transoral gastroplasty, and other "frontier" ... by MISS Executive Director Philip R Schauer, MD, on ... , The five-day CME conference, which will be held ...
... Oct. 27 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and ... McDermott, Endologix President and Chief Executive Officer, said, "Our ... sales of new products by our domestic sales force ...
Cached Medicine Technology:Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego 2Endologix Reports 47% Third Quarter 2009 Revenue Growth 2Endologix Reports 47% Third Quarter 2009 Revenue Growth 3Endologix Reports 47% Third Quarter 2009 Revenue Growth 4Endologix Reports 47% Third Quarter 2009 Revenue Growth 5Endologix Reports 47% Third Quarter 2009 Revenue Growth 6Endologix Reports 47% Third Quarter 2009 Revenue Growth 7Endologix Reports 47% Third Quarter 2009 Revenue Growth 8
(Date:7/7/2015)... Texas (PRWEB) , ... July 07, 2015 , ... ... sensing technologies into everyday items, recently launched their first line of luxury smart ... today and is expected to ship this fall. , “The Socialite ...
(Date:7/7/2015)... ... July 07, 2015 , ... More than ... Dial and Howdy’s, raised more than $524,286 during the Muscular Dystrophy Association's ... $100,000, to help support children fighting muscular dystrophy and related life-threatening diseases ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... services, is debuting their brand new website. The website’s goal is to provide ... wider selection of patient tools, including requesting appointments online. , Part of the ...
(Date:7/7/2015)... ... , ... Greatist today announced the acquisition of Blood, Sweat ... most fun activities to do with friends. , The acquisition of BSC strengthens Greatist’s ... for events, e-commerce, and brand partnerships. , “I’ve been a huge fan of Blood, ...
(Date:7/7/2015)... ... July 07, 2015 , ... SC&H Group, a leading audit, ... to give back to the community through company-wide volunteering efforts. , On an annual ... the day to assisting those in need throughout Baltimore and Washington D.C. ...
Breaking Medicine News(10 mins):Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:SC&H Group Celebrates 9th Annual Day of Service 2
... Breast cancer survivors who experience large weight gain ... to research scientists at the Kaiser Permanente Division of ... survivors who experienced large weight gain (10 percent or ... likely to experience a cancer recurrence compared to women ...
... Center researchers have identified one reason people with hypertension experience ... exercise, and they,ve learned how to prevent the rise. ... of Physiology reported that hypertensive people who exercise undergo ... identified a specific type of blood pressure medication that minimizes ...
... , MONDAY, April 4 (HealthDay News) -- People ... a new study suggests. It also found that a ... substance abuse and mood disorders. Researchers analyzed data from ... in the U.S. National Epidemiologic Survey of Alcohol and Related ...
... Diego School of Medicine say a "stress response" mechanism used ... is exploited by cancer cells, which transmit the same stress ... that can aid tumor growth. The findings are reported ... the Laboratory of Immunology at the UC San Diego Moores ...
... Society, the largest non-government, not-for-profit funding source of cancer ... research and training grants totaling $49,213,000 to 85 institutions ... 2011. The grants go into effect beginning July 1, ... of previous grants. For more than 60 years, ...
... Steven Reinberg HealthDay Reporter , MONDAY, April 4 ... virus that accounts for most cases of cervical cancer, may ... In other smaller studies, HPV has been found in lung ... in the development of the disease is not known, the ...
Cached Medicine News:Health News:Large weight gain raises risk for recurrence among breast cancer survivors 2Health News:Dangerous blood pressure increases during exercise can be blocked, UT Southwestern researchers find 2Health News:Poverty Linked to Anxiety, Mood Disorders 2Health News:Call of the riled 2Health News:American Cancer Society awards new research and training grants 2Health News:American Cancer Society awards new research and training grants 3Health News:American Cancer Society awards new research and training grants 4Health News:American Cancer Society awards new research and training grants 5Health News:HPV Might Be Linked to Lung Cancer 2
... 1000-90 is the most versatile power supply ... to 1000 volts or 1250 milliamps or ... No other 1000 volt power supply is ... large protein gels or small focusing gels ...
... IEF to DNA sequencing, Thermo Series 90 ... routine electrophoretic applications. These power supplies ... or constant power operating modes, with automatic ... power of the Series 90 power supplies, ...
... The MAX POWER Programmable Power ... instruments which can handle virtually any ... high current blotting. It is unique ... displays. The MAX POWER Programmable Power ...
... is a microprocessor-controlled programmable power supply ... current and high current/low voltage applications ... is ideal for sample fractionation, IPG ... The low voltage/high current section is ...
Medicine Products: